Clinical prediction model to characterize pulmonary nodules
With the introduction of CT-screening for lung cancer, the number of solitary pulmonary nodules (SPN) discovered by chest films strongly increased. Yet the diagnosis often remains unclear after noninvasive evaluation. The current model estimates a patients risk of malignancy based on the addition of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) outcomes to a recently described prediction model. 
Research authors: Gerarda J. Herder, Harm van Tinteren, Richard P. Golding, Piet J. Kostense, Emile F. Comans, Egbert F. Smit, Otto S. Hoekstra
Details Formula Study characteristics Files & References
Model author
Model ID
Revision date
MeSH terms
  • Solitary Pulmonary Nodule
  • Lung Cancer
  • Model type
    Custom model (Calculation)

    Additional information

    Between August 1997 and March 2001, all patients with an indeterminate SPN, which had been detected during normal clinical work in both university and community hospital settings, who had been referred for FDG-PET scanning were retrospectively identified from the database of the PET center at the VU University Medical Centre. In our database, the characteristics of all patients are registered using a modified version of the American College of Radiology Index for Radiologic Diagnoses.

    Mean age, yr (SD) in the Malignant tumor group is 66 (10) and in the Benign tumor group 60 (13)

    Study Population

    Total population size: 106
    Males: {{ model.numberOfMales }}
    Females: {{ model.numberOfFemales }}

    Categorical characteristics

    Name Subset / Group Nr. of patients
    Tumor Benign 45
    Malignant 61
    Smoker None 27
    Current or former 79
    Cancer > 5 yrs ago No 96
    Yes 10
    Spicula <50% 64
    ≥50% 42
    Location Upper lobe 70
    Elsewhere 36
    Diameter, mm ≤10 33
    11-20 42
    21-30 31
    FDG-PET uptake Absent 27
    Faint 7
    Moderate 23
    Intense 49
    Clinical prediction model to characterize pulmonary nodules
    Refer to Intended Use for instructions before use
    Evidencio B.V., Irenesingel 19, 7481 GJ, Haaksbergen, the Netherlands

    Related files

    No related files available

    {{ model.survival.PITTitle }}

    {{ model.survival.YNETitle }}

    Notes are only visible in the result download and will not be saved by Evidencio

    The probability of malignancy is: %

    {{ resultSubheader }}
    {{ chart.title }}

    Outcome stratification

    Result interval {{ additionalResult.min }} to {{ additionalResult.max }}

    Conditional information

    Result interpretation

    The current model may assist identification of malignancies in patients included in lung cancer screening programmes. The estimated risks supports decisionmaking regarding utilization of empiric stereotactic body radiation therapy (SBRT)

    {{ file.classification }}

    Calculations alone should never dictate patient care, and are no substitute for professional judgement. See our full disclaimer.

    Please enter a comment of rating
    Comments are visible to anyone

    Model feedback

    No feedback yet 1 Comment {{ model.comments.length }} Comments
    Not rated | On {{ comment.created_at }} {{ comment.user.username }} a no longer registered author wrote:

    Please sign in to enable Evidencio print features

    In order to use the Evidencio print features, you need to be logged in.
    If you don't have an Evidencio Community Account you can create your free personal account at:

    Printed results - Examples {{ new Date().toLocaleString() }}

    Evidencio Community Account Benefits

    With an Evidencio Community account you can:

    • Create and publish your own prediction models.
    • Share your prediction models with your colleagues, research group, organization or the world.
    • Review and provide feedback on models that have been shared with you.
    • Validate your models and validate models from other users.
    • Find models based on Title, Keyword, Author, Institute, or MeSH classification.
    • Use and save prediction models and their data.
    • Use patient specific protocols and guidelines based on sequential models and decision trees.
    • Stay up-to-date with new models in your field as they are published.
    • Create your own lists of favorite models and topics.

    A personal Evidencio account is free, with no strings attached!
    Join us and help create clarity, transparency, and efficiency in the creation, validation, and use of medical prediction models.

    Disclaimer: Calculations alone should never dictate patient care, and are no substitute for professional judgement.